Cover Image
Market Research Report

Global Bispecific Antibodies for Cancer Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 827312
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Bispecific Antibodies for Cancer Market 2019-2023
Published: April 17, 2019 Content info: 117 Pages
Description

About this market

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. Technavio's analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Market Overview

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31178

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET

  • Market segmentation by target
  • Comparison by target
  • CD19/CD3 - Market size and forecast 2018-2023
  • CD30/CD16A - Market size and forecast 2018-2023
  • Market opportunity by target

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
  • Merus
  • Regeneron Pharmaceuticals, Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Bispecific antibodies for cancer under development
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Customer landscape
  • Exhibit 19: Target - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by target
  • Exhibit 21: CD19/CD3 - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: CD19/CD3 - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: CD30/CD16A - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: CD30/CD16A - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by target
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Pipeline for bispecific antibodies for cancer treatment
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Amgen Inc. - Vendor overview
  • Exhibit 46: Amgen Inc. - Product segments
  • Exhibit 47: Amgen Inc. - Organizational developments
  • Exhibit 48: Amgen Inc. - Geographic focus
  • Exhibit 49: Amgen Inc. - Key offerings
  • Exhibit 50: Astella Pharma Inc. - Vendor overview
  • Exhibit 51: Astella Pharma Inc. - Business segments
  • Exhibit 52: Astella Pharma Inc. - Organizational developments
  • Exhibit 53: Astella Pharma Inc. - Key offerings
  • Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview
  • Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings
  • Exhibit 56: Merus - Vendor overview
  • Exhibit 57: Merus - Product segments
  • Exhibit 58: Merus - Key offerings
  • Exhibit 59: Regeneron Pharmaceuticals, Inc. - Vendor overview
  • Exhibit 60: Regeneron Pharmaceuticals, Inc. - Business segments
  • Exhibit 61: Regeneron Pharmaceuticals, Inc. - Organizational developments
  • Exhibit 62: Regeneron Pharmaceuticals, Inc. - Key offerings
  • Exhibit 63: Validation techniques employed for market sizing
Back to Top